The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...

The biggest threat for European pharmaceutical groups currently comes from the United States. President-elect Donald Trump ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Shares of weight-loss drugmakers like Novo Nordisk and Eli Lilly surged after President Biden proposed expanding anti-obesity drug coverage under state health plans. The move could reduce ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

The Swiss aseptic fill-finish manufacturing specialist Baccinex has become the latest in a string of acquisitions by the ...

We recently published a list of the 10 Most Profitable European Stocks to Invest In. In this article, we are going to take a ...

Most drug shortages apply to the same active ingredient across multiple markets while generics see the greatest difficulties.

Embracing industrial symbiosis goes beyond ethical responsibility; it’s a chance for companies to lower costs, reduce ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...